HYDROCHLOROTHIAZIDE W Drug Patent Profile

Which patents cover Hydrochlorothiazide W, and when can generic versions of Hydrochlorothiazide W launch?

Hydrochlorothiazide W is a drug marketed by Watson Labs, Ivax Sub Teva Pharms, Pharmeral, and Roxane. and is included in fifteen NDAs.

The generic ingredient in HYDROCHLOROTHIAZIDE W is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.

Summary for HYDROCHLOROTHIAZIDE W

US Patents:	0
Applicants:	4
NDAs:	15
DailyMed Link:	HYDROCHLOROTHIAZIDE W at DailyMed

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE W

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	HYDROCHLOROTHIAZIDE W/ HYDRALAZINE	hydralazine hydrochloride; hydrochlorothiazide	TABLET;ORAL	085373-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmeral	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	085420-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ivax Sub Teva Pharms	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	083568-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	083666-001	Approved Prior to Jan 1, 1982		DISCN	No	No